| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
New Drug Application for azetukalner in focal seizures submitted to U.S. Food & Drug Administration in September 2026 |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
NDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA |
| 03 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The purpose of this 2026 Equity Incentive Plan (the “Plan”) of Xenon Pharmaceuticals Inc., a company incorporated under the laws of Canada, (the “Company”), is to advance the interests of the Company’s shareholders by enhancing the Compa... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Reported positive topline data from Phase 3 X-TOLE2 study of azetukalner in FOS in March and anticipate NDA submission in Q3 2026 |
| 13 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
2025 INDUCEMENT EQUITY INCENTIVE PLANXENON PHARMACEUTICALS INC. |
| 13 Mar 2026 |
8-K: Other Events
Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders: |
| 12 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Introductory. Xenon Pharmaceuticals Inc., a corporation continued under the federal laws of Canada (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 10,52... |
| 09 Mar 2026 |
8-K: Regulation FD Disclosure
Exhibit 99.2 Phase 3 X-TOLE2 Study: Topline Results MARCH 09, 2026 NASDAQ: XENE xenon-pharma.com |
| 27 Feb 2026 |
8-K: Other Events
RE: At-the-Market Equity Offering Program of Xenon Pharmaceuticals Inc. |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026 |
| 01 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
2025 INDUCEMENT EQUITY INCENTIVE PLANXENON PHARMACEUTICALS INC. |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete |
| 16 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
We are pleased to offer you a position with Xenon Pharmaceuticals USA Inc. (the “Company”), a wholly-owned subsidiary of Xenon Pharmaceuticals Inc. (the “Parent” and, together with the Company, “Xenon”), as Chief Financial Officer, comme... |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026 |
| 03 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
(c) On June 30, 2025, the Board of Directors of Xenon Pharmaceuticals Inc. (the "Company") appointed Ian Mortimer, the Company's President and Chief Executive Officer, to the role of interim Chief Financial Officer and designated him as ... |
| 05 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2025, Xenon Pharmaceuticals Inc. (the “Company”) held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, 72,075,729 of the Company’s common shares, or approximately 94.10% of the total commo... |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 |
| 17 Mar 2025 |
8-K: Other Events
Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders: |
| 05 Mar 2025 |
8-K: Changes in Registrant's Certifying Accountant
We were previously principal accountants for Xenon Pharmaceuticals Inc. (the Company) and, under the date of February 27, 2025, we reported on the consolidated financial statements of the Company as of and for the years ended December 31... |
| 27 Feb 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch |
Loading...